Physician profile
John Frederick Clark
NPI 1174505523
$5,094.93
in general payments reported to CMS, 2019-2025
31 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $837 · 2020: $395 · 2021: $603 · 2022: $716 · 2023: $1,586 · 2024: $517 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,544.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,544.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,595.38 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $630.76 | 2019-2025 | Trelegy Ellipta, Bexsero, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $498.63 | 2019-2025 | Jardiance |
| Amgen INC. | $426.60 | 2019-2025 | Evenity, Otezla, Repatha |
| Abbott Laboratories | $366.52 | 2021-2023 | Freestyle Libre 3 |
| Allergan, INC. | $306.37 | 2019-2020 | |
| Lilly USA, LLC | $297.54 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Novo Nordisk INC | $197.14 | 2021-2025 | Rybelsus, Ozempic |
| Astrazeneca Pharmaceuticals LP | $93.74 | 2019-2025 | Farxiga, Airsupra |
| Sanofi-Aventis U.S. LLC | $78.31 | 2020-2022 | |
| Pfizer INC. | $73.60 | 2019-2024 | |
| Dexcom, INC. | $63.09 | 2021-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $58.24 | 2019-2022 | |
| Radius Health, INC. | $48.67 | 2023 | Tymlos |
| Idorsia Pharmaceuticals US INC | $44.68 | 2023 | Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $40.54 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $36.57 | 2023-2025 | Eliquis |
| Organon LLC | $24.60 | 2023-2025 | Jada System |
| Merck Sharp & Dohme LLC | $23.77 | 2022 | |
| Amarin Pharma, INC. | $21.57 | 2019 | |
| Amag Pharmaceuticals, INC. | $19.90 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $18.53 | 2022 | |
| Philips North America LLC | $17.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $16.26 | 2022 | |
| Sunovion Pharmaceuticals INC. | $14.90 | 2020 | |
| Viiv Healthcare Company | $14.58 | 2023 | Apretude |
| Coopersurgical, INC. | $13.67 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.58 | 2019 | |
| Sanofi Pasteur INC. | $13.58 | 2020 | |
| Roche Diagnostics Corporation | $13.06 | 2019 | |
| Hologic Sales and Service, LLC | $12.63 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.